Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP3574915A1
Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AU2012238643A1
Method for treating IFNalpha related conditions
CA2820837A1
Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2508197A1
Method for treating IFNalpha related conditions
EP2462950A1
Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
AU2007200141A1
New anti-HIV immogens (Toxoids), preparation methods and use for preventing and treating Aids
BRPI0609932A2
methods for preparing an antifungal immunogenic product and for preparing a vaccine composition, antifungal immunogenic product, immunogenic composition, and vaccine composition
US2006252075A1
Method for monitoring anti-HIV treatment in HIV infected individuals
FR2859725A1
High efficiency process for obtaining human antibodies that neutralize the biological activity of a human cytokine
FR2839080A1
Process for preparing a product for expression of dna encoding hpv-16 mute e7 protein by pichia pastoris yeast cells
Product for expression of dna encoding hpv-16 muteted e7 protein, immunogenic composition containing said expression product and process for preparing the same
FR2838444A1
New peptides and their therapeutic application
FR2828404A1
COMPOSITE SUPERIMMUNOGEN FOR BIFUNCTIONAL VACCINE USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH STROMAL TISSUE DISORDER
FR2812813A1
USE OF IMMUNOGENS TO TREAT OR PREVENT WITHIN MALIGNANT TUMORS IMMUNE DISORDERS INDUCED BY EXTRACELLULAR FACTORS
US6200575B1
Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
FR2802426A1
USE OF IMMUNOSUPPRESSIVE AND / OR ANGIOGENIC IMMUNOGENIC PROTEINS MADE INACTIVE FOR THE PRODUCTION OF SECRETORY IGAs
WO0011225A1
Method for determining prognosis of hiv infected individuals
EP1096953A1
Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
